Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Scrip   
Xenoport/GSK's post-shingles pain drug passes Phase IIb trials
21 September 2009
Asher Mullard

Top-line results show that Solzira (gabapentin enacarbil, formerly known as XP13512 and as GSK1838262) relieved neuropathic pain associated with post-herpetic neuralgia (PHN) in adults, report GlaxoSmithKline and Xenoport. Xenoport shares jumped around 25% on September 17th on the news, to close...



Please Login to read the full article.
 
Not a subscriber? Request a FREE Trial Subscribe to Scrip
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Scrip Features Other Informa Features
EVENTS
Today
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm